Lexaria Bioscience (LEXX) Q1 2025 earnings summary

Executive summary

• DehydraTECH technology continues to advance, with new preclinical and clinical studies targeting diabetes, weight loss, and hypertension, including a 12-arm animal study and a human pilot study with tirzepatide capsules.

• Ethics approval was received for a Phase 1b, 12-week chronic study in Australia with 80 overweight, obese, pre- or type 2 diabetic patients, and a project agreement was executed with Novotech for this trial.

• $4.3 million in net proceeds were raised from securities offerings in October 2024, strengthening liquidity for ongoing R&D and operations.

Financial highlights

• Revenue for the quarter ended November 30, 2024, was $183,923, up from $151,278 year-over-year, driven by increased IP licensing and B2B sales.

• Net loss attributable to shareholders was $2.7 million, compared to $1.2 million in the prior year period, reflecting higher R&D and operating expenses.

• Cash and cash equivalents at quarter-end were $8.1 million, up from $6.5 million at the prior year-end.

• Working capital improved to $8.5 million from $6.8 million sequentially.

Outlook and guidance

• Management expects continued significant operational expenses and net losses over the next 12 months as R&D programs expand, particularly in clinical trials for DehydraTECH formulations.

• Current cash resources and expected license revenues are projected to be sufficient to meet financial obligations for at least the next twelve months.